New ResApp data shows 90 percent accuracy when diagnosing range of respiratory conditions

Brisbane, Australia-based ResApp is planning to re-do its big US trial soon, but in the meantime the smartphone respiratory diagnosis company is continuing to collect data in its native country. The company released data yesterday from a clinical study of more than 1,300 adult patients at Joondalup Health Campus in Perth and Wesley Hospital in Brisbane. While the company's previous studies have focused on a particular condition, this is the first real-world study of patients with a wide variety of diagnoses. Patients presented with a range of respiratory conditions, including some with no condition at all. "Delivering accurate results within an adult intended use population is an excellent step forward, further demonstrating that ResApp's algorithms can be applied effectively in a group of patients with a very broad range of respiratory illnesses," Tony Keating, CEO and managing director of ResApp Health, said in a statement.